

**(12) STANDARD PATENT**  
**(19) AUSTRALIAN PATENT OFFICE**

(11) Application No. **AU 2009256457 B2**

(54) Title  
**Cell line, system and method for optical control of secondary messengers**

(51) International Patent Classification(s)  
**A61K 48/00** (2006.01) **C12P 21/06** (2006.01)  
**C12P 21/04** (2006.01)

(21) Application No: **2009256457** (22) Date of Filing: **2009.05.29**

(87) WIPO No: **WO09/148946**

(30) Priority Data

(31)	Number	(32)	Date	(33)	Country
	<b>61/057,108</b>		<b>2008.05.29</b>		<b>US</b>

(43) Publication Date: **2009.12.10**

(44) Accepted Journal Date: **2014.06.26**

(71) Applicant(s)  
**The Board of Trustees of the Leland Stanford Junior University**

(72) Inventor(s)  
**Airan, Raag D.;Deisseroth, Karl**

(74) Agent / Attorney  
**FB Rice, Level 23 44 Market Street, Sydney, NSW, 2000**

(56) Related Art  
**MARIN E. P., et al, "The amino terminus of the fourth cytoplasmic loop of rhodopsin modulates rhodopsin-transduction interaction", Journal of Biological Chemistry, 2000, vol 275, pages 1930-1936**  
**KIM J-M., et al, "Light-driven activation of ss2-adrenergic receptor signaling by a chimeric rhodopsin containing the ss2-adrenergic receptor cytoplasmic loops", Biochemistry, 2005, vol 44, pages 2284-2292**  
**WO 2003/016486 A2**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



PCT



(43) International Publication Date  
10 December 2009 (10.12.2009)

(10) International Publication Number  
**WO 2009/148946 A3**

(51) International Patent Classification:

C12P 21/06 (2006.01) C12P 21/04 (2006.01)

(21) International Application Number:

PCT/US2009/045611

(22) International Filing Date:

29 May 2009 (29.05.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/057,108 29 May 2008 (29.05.2008) US

(71) Applicant (for all designated States except US): **THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY** [US/US]; 1705 El Camino Real, Palo Alto, CA 94306-1106 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **AIRAN, Raag, D.** [US/US]; 610 Gilbert Avenue #9, Menlo Park, CA 94025 (US). **DEISSEROTH, Karl** [US/US]; 70 Peter Coutts Circle, Palo Alto, CA 94305 (US).

(74) Agent: **CRAWFORD, Robert, J.**; Crawford Maunu PLLC, 1150 Northland Drive, STE 100, St. Paul, MN 55120 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:

25 February 2010

(54) Title: CELL LINE, SYSTEM AND METHOD FOR OPTICAL CONTROL OF SECONDARY MESSENGERS

(57) Abstract: A variety of methods, devices and compositions are implemented for light- activated molecules. One such method is implemented for generating secondary messengers in a cell. A nucleotide sequence for expressing a chimeric light responsive membrane protein (e.g., rhodopsin) is modified with one or more heterologous receptor subunits {e.g., an adrenergic receptor (alpha1, Beta2)}. The light responsive membrane protein is expressed in a cell for producing a secondary messenger in response to light.



WO 2009/148946 A3

**CELL LINE, SYSTEM AND METHOD FOR  
OPTICAL CONTROL OF SECONDARY MESSENGERS**

**Related Patent Document**

5           This patent document claims the benefit, under 35 U.S.C. § 119(e), of U.S. Provisional Patent Application Serial No. 61/057,108 filed on May 29, 2008 and entitled "Cell Line, System and Method for Optical Control of Secondary Messengers;" the underlying provisional application is fully incorporated herein by reference.

**Incorporation-by-Reference of Material Submitted Electronically**

10           Incorporated by reference in its entirety is a computer-readable nucleotide/ amino acid sequence listing submitted concurrently herewith, and identified as follows: One 12,342 Byte ASCII (Text) file named "STFD195PCT\_ST25.txt" created on April 29, 2009.

**Field of the Invention**

15           The present invention relates generally to systems and approaches for generating secondary messengers in response to optical stimulus and more particularly to a cell lines, nucleotide sequences, chimeric proteins, and uses thereof, each relating to the production of secondary messengers in response to light.

**Background**

20           Guanine nucleotide-binding proteins (G proteins) are believed to alternate between an inactive guanosine diphosphate (GDP) state and an active guanosine triphosphate (GTP) bound state. These two states have been linked to the release of a secondary messenger within a cell. The released secondary messenger can function to  
25           regulate downstream cell processes.

            Secondary messengers include signaling molecules that are rapidly generated/released. These molecules produce cellular responses by activating effector proteins within the cell. Example cellular signaling systems include the phosphoinositol system, the cyclic adenosine monophosphate (cAMP) system, and the arachidonic acid  
30           system.

            Changes between the different states of the G proteins can be triggered as a result of proteins called G protein-coupled receptors (GPCRs), G protein-linked receptors (GPLR), seven transmembrane domain receptors (7TM receptors) or heptahelical

receptors. This protein family includes a variety of transmembrane receptors. These receptors respond to external stimuli (*e.g.*, light, neurotransmitters, odors or hormones) by activating signal transduction pathways internal to the cell. Specifically, ligands bind and activate the transduction pathways thereby causing the G proteins to alternate states.

5 GPCR-related activity is associated with many diseases, and thus, GPCRs are the target of many pharmaceuticals and treatments.

It is believed that over 30% of all drugs on the market target G-protein coupled receptors (GPCRs) and that many of those drugs relate to the production or inhibition of the secondary messenger cAMP. There is an abundance of pathological processes that

10 directly involve cAMP, including neurophysiological, endocrinological, cardiac, metabolic, and immune diseases. In the study of complex mammalian behaviors, technological limitations have prevented spatiotemporally precise control over intracellular signaling processes. Current chemical-based methods for modulating secondary messenger levels, such as cAMP levels, operate relatively slowly and present

15 problems to study activity on the fast timescales that the body uses in connection with certain tissue, such as in nervous or cardiac tissue. These chemical-methods often lack the speed to probe these fast timescales (*e.g.*, while screening for novel therapeutics).

Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is not to be taken as an

20 admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present disclosure as it existed before the priority date of each claim of this application.

Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated

25 element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

### Summary

The present invention is directed to overcoming the above-mentioned challenges and others related to generation of secondary messengers and related imaging devices and

30 their implementations. The present invention is exemplified in a number of implementations and applications, some of which are summarized below.

In one aspect, the invention provides a method for generating secondary messengers in a cell, the method comprising: expressing in the cell a chimeric light-responsive fusion protein comprising a light-responsive rhodopsin-based membrane protein and a heterologous alpha-1 adrenergic receptor, wherein said expression provides  
5 for production of a secondary messenger in response to light, and wherein the chimeric light-responsive fusion protein comprises an amino acid sequence having at least 85% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO: 4, wherein the cell expresses a secondary messenger-targeted cation channel that is responsive to the secondary messenger; and visualizing resultant activity using a cation-  
10 sensitive dye.

In another aspect, the present invention provides a method for assessing the efficacy of a treatment regimen relating to intracellular messengers, the method comprising: expressing a chimeric light-responsive fusion protein comprising a light-responsive rhodopsin-based membrane protein and a heterologous alpha-1 adrenergic  
15 receptor in a mammalian cell, wherein said expression provides for production of a secondary messenger in response to light, and wherein the chimeric light-responsive fusion protein comprises an amino acid sequence having at least 85% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO: 4; wherein the cell expresses a secondary messenger-targeted cation channel that is responsive to the  
20 secondary messenger; exposing the chimeric light-responsive fusion protein to light; and assessing the effects of the treatment by visualizing resultant activity using a cation-sensitive dye.

In another aspect, the present invention provides a cell suitable for use in a method of the invention, the cell expressing: a) a chimeric light responsive rhodopsin-based  
25 membrane protein with one or more heterologous alpha-1 receptor subunits, wherein the chimeric protein produces a second messenger, and wherein the chimeric protein comprises an amino acid sequence having at least 85% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO: 4; and b) a secondary messenger-targeted cation channel that is responsive to the second messenger.

30 In another aspect, the present invention provides a cell suitable for use in the method of the invention, the cell expressing a polypeptide comprising an amino acid sequence having at least 90% amino acid sequence homology to the amino acid sequence set forth in SEQ ID NO: 4.

In another aspect, the present invention provides a non-human transgenic mammal comprising a cell expressing a chimeric light-responsive fusion protein comprising a light-responsive rhodopsin-based membrane protein and a heterologous alpha-1 adrenergic receptor, wherein the chimeric light-responsive fusion protein comprises an amino acid sequence having at least 85% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO: 4, wherein expression of the fusion protein in the cell provides for production of a secondary messenger in the cell in response to light.

In another aspect, the present invention provides a chimeric light-responsive fusion protein comprising a light-responsive rhodopsin-based membrane protein and a heterologous alpha-1 adrenergic receptor, wherein the chimeric light-responsive fusion protein comprises an amino acid sequence having at least 85% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO: 4.

In another aspect, the present invention provides a nucleic acid molecule encoding a chimeric light-responsive fusion protein, wherein the chimeric light-responsive fusion protein comprises a light-responsive rhodopsin-based membrane protein and a heterologous alpha-1 adrenergic receptor, and wherein the nucleic acid molecule has at least 90% nucleotide sequence identity to SEQ ID NO: 3.

In another aspect, the present invention provides a recombinant expression vector comprising a nucleic acid molecule of the invention.

In another aspect, the present invention provides a cell genetically modified with a nucleic acid molecule of the invention or a vector of the invention.

Consistent with an embodiment of the present invention, a method is implemented for generating secondary messengers in a cell. A nucleotide sequence for expressing a chimeric light responsive membrane protein (e.g., rhodopsin) is modified with one or more heterologous receptor subunits {e.g., an adrenergic receptor (alpha, Beta2)}. The light responsive membrane protein is expressed in a cell for producing a secondary messenger in response to light.

Consistent with an embodiment of the present invention, a method is implemented for assessing the efficacy of a putative treatment regimen (e.g., a drug or electrical stimulus or anything that works via these secondary messengers) relating to intracellular messengers. A nucleotide sequence for expressing a chimeric light responsive membrane protein (rhodopsin) is modified with one or more heterologous receptor subunits {e.g., an

adrenergic receptor ( $\alpha 1$ ,  $\beta 2$ ). The light responsive membrane protein is expressed in a cell for producing a secondary messenger in response to light. The protein is exposed to light. The effects of the treatment are assessed.

An embodiment of the present invention is directed toward, a cell expressing a  
5 chimeric light responsive membrane protein (rhodopsin) with one or more heterologous receptor subunits {e.g., an adrenergic receptor ( $\alpha 1$ ,  $\beta 2$ )}.

An embodiment of the present invention is directed toward, a nucleotide sequence for expressing a chimeric light responsive membrane protein (rhodopsin) with one or more heterologous receptor subunits {e.g., an adrenergic receptor ( $\alpha 1$ ,  $\beta 2$ )}.

10 The above summary of the present invention is not intended to describe each illustrated embodiment or every implementation of the present invention. The figures and detailed description that follow more particularly exemplify these embodiments.

### Brief Description of the Drawings

The invention may be more completely understood in consideration of the detailed  
15 description of various embodiments of the invention that follows in connection with the accompanying drawings, in which:

FIG. 1A shows a schematic showing optoGs and optoGq, consistent with example embodiments of the present invention;

FIG. 1B shows Enzyme-Linked Immunosorbent Assay (ELISA) of cAMP, cGMP,  
20 and  $IP_1$  of cells transfected with either nothing, optoGs, or optoGq, consistent with example embodiments of the present invention;

FIG. 1C shows Ca-imaging of cells transfected with mCherry fusion proteins of optoGs and optoGq, consistent with example embodiments of the present invention;

FIG. 2 shows Ca-imaging of cells transfected with mCherry fusion proteins of  
25 optoGs and optoGq, consistent with example embodiments of the present invention;

FIG. 3A shows cAMP,  $IP_1$  and  $IP_3$  levels for HEK cells expressing various constructs, consistent with example embodiments of the present invention;

FIG. 3B shows a lentiviral express vector, GAD immunostaining of opto- $\alpha_1$ AR-expressing cells and observed pCREB activation in optoXR-expressing cells (mCherry+)  
30 following 10 min optical stimulation, consistent with example embodiments of the present invention;

FIG. 4A shows optrode targeting of transduced accumbens, spike waveforms and baseline firing rates for indicated constructs, consistent with example embodiments of the present invention;

FIG. 4B shows *in vivo* optrode recordings with light stimulation, consistent with  
5 example embodiments of the present invention;

FIG. 4C shows change in spiking frequency with light versus baseline, consistent with example embodiments of the present invention;

FIG. 4D shows firing rate change kinetics, consistent with example embodiments of the present invention;

10 FIG. 5A shows stereotactic targeting of a transduced region, a freely moving mouse with implanted fiber optics, a schematic of place preference apparatus and test and a trace of a freely exploring mouse, consistent with example embodiments of the present invention;

FIG. 5B shows preferences for control and opto- $\alpha_1$ AR, consistent with example  
15 embodiments of the present invention; and

FIG. 5C shows results of total distance for various open field tests; consistent with example embodiments of the present invention.

While the invention is amenable to various modifications and alternative forms, specifics thereof have been shown by way of example in the drawings and will be  
20 described in detail. It should be understood, however, that the intention is not to limit the invention to the particular embodiments described. On the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention.

### Detailed Description

The present invention is believed to be useful for enabling practical applications  
25 of a variety of optical-based systems and methods, and the invention has been found to be particularly suited for use in systems and methods dealing with optical control of secondary messenger levels within a cell. While the present invention is not necessarily limited to such applications, various aspects of the invention may be appreciated through a discussion of various examples using this context.

30 Embodiments of the present invention involve a chimeric membrane protein that responds to optical stimulus by causing the release of a secondary messenger within the cell. In a specific instance, the chimeric protein is a combination of a heterologous



receptor subunit and a protein that undergoes conformation in reaction to light via photoisomerization and thus is activated by light. Rhodopsins or retinylidene proteins provide an example group of light-responsive proteins that can be modified to include a heterologous receptor subunit.

5           According to an embodiment of the present invention, a protein believed to contain a seven transmembrane  $\alpha$ -helical domain is modified to include a heterologous receptor subunit associated with a secondary messenger. When expressed in a cell membrane, the protein reacts to light by undergoing a conformational change. The conformational change triggers the release/production of the secondary messenger.

10           Embodiments of the present invention involve a nucleotide sequence for coding a chimeric membrane protein that responds to optical stimulus by causing the release of a secondary messenger within the cell.

            Embodiments of the present invention involve a cell that expresses a heterologous and chimeric membrane protein. The chimeric membrane protein responds to optical stimulus by triggering the release of a secondary messenger within the cell. In certain  
15           embodiments the expression of the chimeric membrane protein occurs *in vivo*. In other embodiments expression of the chimeric membrane protein occurs *in vitro*.

            Embodiments of the present invention can be implemented for production of any suitable secondary messenger by modifying a Guanine nucleotide-binding protein  
20           coupled receptor protein (GPCR) to include the appropriate receptor subunit.

            Embodiments of the present invention allow for the use of proteins that respond to a variety of wavelengths and intensities of light.

            An embodiment of the present invention involves the use of a chimeric GPCR protein, as disclosed herein, to determine any downstream effect of the secondary  
25           messenger activity of interest.

            Embodiments of the present invention are directed to expression of a chimeric GPCR protein in a variety of cell types including, but not limited to, mammalian cells, stem cells, plant cells, and unicellular organisms like yeast and *E. coli*.

            A specific embodiment of the present invention is related to an optimized  
30           expression of a chimeric protein with attached fluorescent proteins for ease of visualization, and optimized use of the modality for studying downstream effects of the secondary messenger activity induced by light.

An embodiment of the present invention is directed to genetically targeting a chimeric GPCR protein, as disclosed herein, to specific cell populations for expression therein. Cell-type specific promoters exist that are selectively expressed in a target cell type (*e.g.*, Synapsin-1 for targeting neurons; Troponin variants for cardiac tissue).

- 5 Placing these promoters upstream of the chimeric GPCR protein in an expression vector can be used to target expression of the protein to a cell type of interest. This includes inducible, reversible, or otherwise controllable promoter systems such as Tet-response, ER-response, and Cre/Lox systems.

- According to an example embodiment of the present invention, a genetically  
10 encodeable protein is developed such that, when these are expressed in cell types of interest, cyclic adenosine monophosphate (cAMP) is produced in response to light. This can be useful, for example, to visualize downstream effects on cell physiology including, but not limited to, screening for pharmaceuticals. Other embodiments use a chimeric and heterologous GPCR that results in the release of secondary messengers in response to  
15 light. Example secondary messengers include cAMP, cyclic guanosine monophosphate (cGMP), inositol trisphosphate/inositol 1,4,5-trisphosphate/triphosphoinositol (IP<sub>3</sub>) and arachidonic acid.

- Consistent with an embodiment of the present invention, a method is implemented for assessing the efficacy of a putative treatment regimen (*e.g.*, a drug or electrical  
20 stimulus or anything that works via these secondary messengers) relating to intracellular messengers. A nucleotide sequence for expressing a chimeric light responsive membrane protein (*e.g.*, rhodopsin) is modified with one or more heterologous receptor subunits {*e.g.*, an adrenergic receptor ( $\alpha$ 1,  $\beta$ 2)}. The light responsive membrane protein is expressed in a cell for producing a secondary messenger in response to light. The protein  
25 is exposed to light. The effects of the treatment are assessed.

- The light can be applied according to a desired stimulus profile. In one embodiment the expressed membrane protein responds to light within tens of milliseconds. Thus, the stimulus profile can include a series of light pulses in rapid succession and the resulting effects can be monitored using, for example, Ca<sup>2+</sup> sensitive  
30 dyes.

In one instance, the cell can first be stimulated without the treatment. Once the treatment is administered, the cell can then be stimulated again. The results of each test can be compared to assess the effectiveness of the treatment.

The treatment can include a wide variety of different implementations including, but not limited to, pharmaceuticals, modifications to the cell (genetic or otherwise), physical parameters of the cell (*e.g.*, temperature changes or electrical stimulus) or a treatment regimen applied to an organism.

5        In one embodiment, the treatment is the optical stimulus of the expressed membrane protein. In such an instance the effectiveness can be measured, for example, by monitoring the symptoms associated with a disorder to be treated.

         In another embodiment, the treatment regimen is implemented as part of modeling a disease or disorder. For example, a disease model can be used (cells or animals) and the  
10 background/baseline state can be assessed before the protein is expressed and the treatment regimen evaluated.

         Experimental results show that optically-evoked cAMP regulation of targeted ion channels can be visualized by transfecting cells with both the cAMP-inducer and a cAMP-targeted cation channel and visualizing resultant activity using  $\text{Ca}^{2+}$ -sensitive  
15 dyes. This suite of genetically-encodable, optically-activated modulators of secondary messenger activity can be useful in screening novel therapeutics as well as being a therapeutic modality itself, given the implication of cAMP in numerous diseases states, like ADHD and cardiac channelopathies. The protein can be engineered for use with various other secondary messengers (*e.g.*,  $\text{IP}_3$ ), other colors for light activation by  
20 engineering the retinal binding site or choosing for the chimera a rhodopsin or cone opsin with a different absorbance/action spectrum, and other downstream effects of the secondary messenger, such as calcium signaling and/or kinase activity.

         FIGs. 1A, 1B and 1C show experimental data from optoGs and optoGq, two examples of light-activated inducers of secondary messenger signaling ('optoXRs') that  
25 have been developed. These light-activated inducers are a rhodopsin/GPCR chimerism. OptoGq provides light-responsive control of Gq signaling, whereas, OptoGs, provides light-responsive control of Gs signaling.

         In both optoGs and optoGq it has been shown that there is negligible difference in baseline cAMP and  $\text{IP}_3$  levels in darkness and that there is no crossover to other  
30 secondary messenger pathways such as cGMP. The increased cAMP levels seen with light stimulation of optoGq is an expected downstream effect of  $\text{IP}_3$  production.

         FIG. 1A shows a schematic of optoGs and optoGq, consistent with example embodiments of the present invention. For each protein, the intracellular loops of

rhodopsin are replaced with those of adrenergic proteins normally coupled to either Gs (beta2) or Gq (alpha1). The genetic coding sequences are optimized for expression in human and murine cells. Examples of the resulting sequences include optoGs: Seq. Id. No. 1 and Seq. Id. No. 2; and optoGq: Seq. Id. No. 3 and Seq. Id. No. 4.

- 5 As is appreciated by the skilled artisan, the amino acid sequences of the proteins are presented as non-limiting examples in support of embodiments which extend to variations (*e.g.*, point mutations) in the genetic sequence that otherwise provide consistent, interchangeable or equivalent results.

FIG. 1B shows Enzyme-Linked Immunosorbent Assay (ELISA) of cAMP (top),  
10 cGMP (middle), and IP<sub>1</sub> (bottom; a degradation product of IP<sub>3</sub>) of cells transfected with either nothing, optoGs, or optoGq, consistent with an example embodiment of the present invention. The results of FIG. 1B were obtained from cells that were stimulated with 504 nm light (20 nm bandwidth) for one minute per spot or kept in the dark, as indicated.

Stimulation was implemented using an environment-controlled inverted culture  
15 microscope (Leica DMI6000B). In the cAMP assay, some cells were treated with 10uM forskolin for 30 minutes as a saturating, positive control of the assay. OptoGs significantly increased cAMP levels in response to light. No significant baseline increase of cAMP, or deviations of cGMP or IP<sub>3</sub> levels with optoGs were found. OptoGq significantly increased IP<sub>3</sub> levels in response to light without significantly altering cGMP  
20 levels. An increase in cAMP levels with IP<sub>3</sub> production is believed to be a consequence of intracellular Ca<sup>2+</sup> release.

FIG. 1C shows Ca-imaging of cells transfected with mCherry fusion proteins of optoGs and optoGq, consistent with example embodiments of the present invention. To detect cAMP, a cAMP-selective mutant of the cyclic nucleotide gated Ca<sup>2+</sup> channel  
25 CNGA2 was transfected in excess of optoGs. IP<sub>3</sub> activates release of intracellular Ca<sup>2+</sup> stores, thereby providing a reliable signal of Gq activation. A control population was also transfected with mCherry alone with the mutant CNGA2 in excess. Cells were loaded with fura-2 (20-25 minute incubation) and 2 ms exposures of 340 nm and 380 nm were acquired every two seconds. In each of optoGs and optoGq the acquisitions alone were  
30 sufficient to yield a Ca signal, while no significant signal was detected in the control population.

FIG. 1 shows data obtained from a specific experimental setup, however, the invention is not so limited. For example, various deliver techniques other than

transfecting are contemplated including, but not limited to, viral transduction, ballistic gene delivery (gene gun), and spontaneous nucleic acid uptake.

The base-rhodopsin can be modified for use with any suitable heterologous receptor subunits, such as Gi- coupled receptors like the alpha2-adrenergic receptor or the dopamine D2 receptor or the serotonin 5HT2A receptor; or other Gs- or Gq-coupled  
5 receptors like the dopamine D1A receptor or the metabotropic glutamate receptors.

According to one example embodiment, the base-rhodopsin is a protein derived from the bovine *Bos taurus*.

According to one embodiment the base-protein other than the base-rhodopsin  
10 mentioned above can also be used and includes various 7-transmembrane proteins, such as the cone opsins (red, green, or blue), rhodopsins of other species, and ligand-gated receptors like the dopamine or serotonin receptors.

Various implementations relate to *in vivo* applications in mammals. These implementations include, but are not limited to, testing and confirming neural circuit and  
15 disease models.

FIGs. 3A and 3B show experimental data from an *in vivo* application of optoGs (opto- $\beta_2$ AR) and optoGq (opto- $\alpha_1$ AR), which are two examples of light-activated inducers of secondary messenger signaling. Aspects of the present invention relate to the use and development of a versatile family of genetically encoded optical tools  
20 ('optoXRs') that leverage common structure-function relationships among G-protein-coupled receptors (GPCRs) to recruit and control, with high spatiotemporal precision, receptor-initiated biochemical signaling pathways.

The results shown in FIGs. 3A and 3B relate to two specific optoXRs that selectively recruit distinct, targeted signaling pathways in response to light. The two  
25 optoXRs exerted opposing effects on spike firing in nucleus accumbens *in vivo*, and precisely timed optoXR photostimulation in nucleus accumbens by itself sufficed to drive conditioned place preference in freely moving mice. The optoXR approach allows testing of hypotheses regarding the causal impact of biochemical signaling in behaving mammals, in a targetable and temporally precise manner.

30 Optical control over intracellular signaling was implemented in mammals, using shared structure-function relationships among GPCRs to develop and express *in vivo* multiple distinct opsin/GPCR2 chimeras with novel transduction logic that couples signal to effector. Consistent with various implementations, one or more chimeric opsin-

receptor proteins are engineered to be functional within mammals *in vivo*, targetable to specific cells, and responsive to precisely timed light pulses. Such approaches allow for the use of high-speed optical stimulus (and protein response) to test for and characterize intracellular biochemical events at precisely-defined and behaviorally-relevant times. A few non-limiting example implementations include, pulsatile versus tonic modulation, synchrony between different modulatory systems, and other fundamental physiological and pathological processes in defined cell types over a range of timescales.

Mammalian implementations have been successfully implemented. In one example implementation, the intracellular loops of rhodopsin were replaced with those of specific adrenergic receptors by first aligning conserved residues of the Gq-coupled human  $\alpha_{1a}$  adrenergic receptor ( $\alpha_1$ AR) and the Gs-coupled hamster  $\beta_2$ -adrenergic receptor ( $\beta_2$ AR) with the Gt-coupled bovine rhodopsin (FIG. 1A). Exchanges of intracellular regions (including carboxy-terminal domains) were engineered for each receptor based on structural models to transfer G-protein coupling from Gt, and optimized each receptor for *in vivo* expression in mammals. Upon activation by varied ligands, the native receptors can explore multiple ensemble states to recruit canonical and non-canonical pathways in a ligand-biased signaling phenomenon. The optoXRs are likely to select a single active ensemble state upon sensing light in a manner dependent on biological context.

Genes encoding chimeras (opto- $\alpha_1$ AR and opto- $\beta_2$ AR) were fused to a fluorescent protein. Validation of functional optoXR expression, was accomplished through imaged  $[Ca^{2+}]_i$  (intracellular calcium concentration) in HEK cells transfected with opto- $\alpha_1$ AR alone (expected to recruit  $[Ca^{2+}]_i$  via Gq), or with both opto- $\beta_2$ AR (expected to recruit cyclic AMP via Gs) and the cAMP-gated  $Ca^{2+}$  channel CNGA2-C460W/E583M. Ratiometric  $[Ca^{2+}]_i$  imaging demonstrated that 60 s of green light stimulation (504 +/- 6 nm, 7 mW mm<sup>-2</sup>) was sufficient to drive prominent  $[Ca^{2+}]_i$  signals downstream of either optoXR but not in control conditions (FIG. 2), revealing functional expression. To test specificity of the signaling controlled by each optoXR, transduced HEK cells were illuminated with 3 mW mm<sup>-2</sup> 504 +/- 6 nm light for 60 s and then lysed and analyzed for levels of cGMP, cAMP and IP<sub>1</sub> (a degradation product of IP<sub>3</sub>) via immunoassays. The canonical pattern was as expected for opto- $\beta_2$ AR corresponding to its molecular design, as optical stimulation yielded significant production of cAMP in opto- $\beta_2$ AR-expressing cells (FIG. 3A, top), comparable to that achieved with pharmacological stimulation of the wild-type  $\beta_2$ AR and without recruitment of IP<sub>3</sub> (FIG. 3A, middle),  $[Ca^{2+}]_i$  (FIG. 2), or

substantial dark activity. In contrast, optical stimulation yielded significant upregulation of IP<sub>3</sub> signaling in opto- $\alpha_1$ AR-expressing cells (FIG. 3A, middle), comparable to levels induced by pharmacological stimulation of the wild-type  $\alpha_1$ AR. Together with the [Ca<sup>2+</sup>]<sub>i</sub> elevations (FIG. 2), these data reveal the pattern expected for Gq recruitment, a pattern  
5 not seen in opto- $\beta_2$ AR-expressing cells (FIG. 3A, top). Optical stimulation of cells expressing either construct was unable to modulate cGMP levels (FIG. 3A, bottom), further indicating the signaling specificity of the chimeric proteins. Similar assays revealed that the optoXRs retain an action spectrum close to that of native rhodopsin, are able to integrate signals over a range of biologically suitable light fluxes, and can activate  
10 non-canonical pathways to a similar extent as wild-type receptors, as for p42/p44-MAPK signaling.

OptoXR performance in intact neural tissue has been tested, including whether or not supplementation of retinal cofactors was necessary. In one such test, lentiviral vectors carrying the optoXR fusion genes under control of the synapsin-I promoter (to  
15 target biochemical modulation to local neurons rather than other potentially Gs/Gq-responsive cellular tissue elements such as glia and endothelial cells; FIG. 3B, top left) were stereotactically injected into the nucleus accumbens of adult mice. This strategy targets biochemical modulation to neurons with somatodendritic compartments in accumbens (~95% GABAergic medium spiny neurons, without further subtype  
20 specificity; FIG. 3B, left) and excludes fibers of passage or afferent presynaptic terminals as these lentiviruses do not transduce cells via axons. Two weeks after transduction, acute coronal slices of accumbens were prepared in artificial cerebrospinal fluid, optically stimulated for 10 min, and immediately fixed and stained for Ser 133-phosphorylated CREB (pCREB), a biochemical integrator of both cAMP and Ca<sup>2+</sup>-coupled signaling  
25 cascades. Without supplementation of exogenous retinoids, significantly elevated pCREB was observed in the optoXR-expressing populations (FIG. 3B, right) and not in non-illuminated tissue.

The functional consequences of optoXR activation on accumbens local electrical activity was determined by recording multi-unit *in vivo* neuronal firing with an optrode  
30 targeted to transduced accumbens (FIG. 4A). No significant differences in baseline firing rates were observed in the dark with either construct (FIG. 4A, bottom right). Optical stimulation resulted in decreased network firing in opto- $\beta_2$ AR-expressing accumbens (left trace in FIG. 4B illustrates effect kinetics; summary data shown in FIG. 4C and 4D

respectively), in agreement with previous pharmacological studies targeting Gs. Optical stimulation increased firing in opto- $\alpha_1$ AR-expressing accumbens (FIG. 4B right; FIG. 4C, 4D). Spike frequency histograms showed that the kinetics of optoXR effects on firing rates was consistent with biochemical rather than electrical initiation of the signal (FIG. 4D). These electrophysiological data, in combination with the earlier biochemical

5 validations, support that optoXRs can be functionally expressed *in vivo*, to permit differential photoactivatable control of intracellular cascades and to modulate network physiology.

In one implementation, optogenetics were used to assess the ability of precisely

10 timed optoXR stimulation to modulate behavior in freely moving mice. Portable solid-state light delivery was combined with transgenic expression of optoXRs to optically control intracellular signaling within accumbens neurons in the temporally precise manner used for operant behavior (FIG. 5A). Confocal analysis revealed expression to be limited to local accumbens neurons; in particular no labeling was observed in afferent

15 fibers, in distant regions projecting to accumbens, in glia, or in surrounding regions. Optical stimulation was targeted to transduced accumbens as part of a three-day operant conditioned place preference assay (FIG. 5A). On each day of the test, animals were allowed to freely explore the place preference apparatus (FIG. 5A, bottom). On day 1, animals freely explored the apparatus without optical stimulation. On day 2, whenever

20 the animal freely entered the designated conditioned chamber, a laser-diode-coupled optical fiber registered to the transduced region delivered light pulses at 10 Hz to approximate the likely intensity of monoaminergic input during strong reward. Path tracing revealed that the flexible optical fiber approach allowed full and unimpeded exploration of all chambers (FIG. 5A, bottom). On day 3, animals again freely explored

25 the apparatus without optical stimulation, and the time spent in the conditioned chamber was quantified by two independent, blinded scorers. Notably, animals expressing opto- $\alpha_1$ AR showed a robust increase in preference for the conditioned side of the apparatus following optical stimulation (FIG. 5B). This effect of temporally precise biochemical modulation was reproducible across two separate cohorts of opto- $\alpha_1$ AR animals (n=5–6,

30 P<0.05, Student's t-test for each cohort for time in conditioned chamber; n=11, P<0.01 for the total population), whereas the other opsin genes, opto- $\beta_2$ AR and ChR2, appeared less effective in driving preference. The effect of opto- $\alpha_1$ AR stimulation in accumbens neurons was specific to reward-related behavior and did not extend to direct modulation



of anxiety-related behaviors or locomotor activity, as identical optical stimulation delivered to a cohort of the same animals in an open field test revealed no significant effect on distance travelled or preference for wall proximity (FIG. 5C).

A specific and non-limiting implementation that is consistent with the above experiments is now described. *In vivo* recording and analysis was performed using optrodes consisting of a multi-mode optical fiber 200  $\mu$ m in diameter (Thorlabs) coupled to a recording electrode (1MV tungsten, A-M Systems) with an electrode/fiber tip-to-tip distance of 200–400  $\mu$ m were lowered into the transduced accumbens (electrode tip 4.8–5.2mm below bregma) of mice placed in a stereotactic frame (David Kopf Instruments) and anaesthetized under isoflurane. Light from a 473nm diode laser (CrystaLaser) was delivered through the fiber. Electrical signals were bandpass filtered and amplified (0.3–1 kHz, 1800 Microelectrode AC Amplifier, A-M Systems) and analyzed with pClamp 10.0 (Molecular Devices). Spikes were detected by threshold and individually confirmed by inspection.

Behavioral analysis was performed using optical stimulation that was applied through an optical fiber (200  $\mu$ m diameter, Thor Labs) coupled to a 473 nm blue diode laser (CrystaLaser) and registered with a cannula targeting accumbens (0–100 mm from tip). Light was delivered with 50 ms pulse width for optoXRs via a function generator (Agilent 33220A). Place preference was conducted in a standard apparatus (SD Instruments) with walls between chambers removed to permit free exploration. Data were analyzed from video for amount of time spent in each chamber by two independent, blinded observers using a custom tallying script run in MATLAB (Mathworks). For open field tests, animals were placed in a square open field measuring 40340 cm<sup>2</sup>; light stimulation was delivered with the same parameters as for place preference experiments. Videos were analyzed using automated software (Viewpoint), for total time and distance in the central 15315 cm<sup>2</sup> square versus the outer annulus (remainder of the field).

Statistical analysis, where indicated, was performed using two-tailed Student's t-tests (calculated in Microsoft Excel) or one-way ANOVA with Tukey post-hoc tests (GraphPad Prism) were used. All summary bar graphs are presented as mean  $\pm$  s.e.m., with significance denoted as follows: \*P<0.05, \*\*P<0.01, \*\*\*P<0.001.

Further details supporting the surprising results and effectiveness of various embodiments of the present invention can be found in *Temporally precise in vivo control*

of intracellular signalling, Raag D. Airan, *et al.*, *Nature* 458, 1025-1029 (23 April 2009), which is fully incorporated herein by reference.

The following description provides details for specific and non-limiting method that is consistent with an embodiment of the present invention. Numerous variations of this methodology are envisioned and within the scope of the present invention.

#### *Vector construction*

Mammalian codon optimized sequences of opto- $\alpha_1$ AR and opto- $\beta_2$ AR (amino acid sequences in FIG. 1A) were synthesized and cloned into pcDNA3.1, and fused to the N-terminus of mCherry or YFP (with its start codon deleted) using the NotI site. The linker between the optoXR and mCherry/YFP is 5' GCGGCCGCC 3'. Lentiviral vectors containing Synapsin I optoXR mCherry were constructed by cloning the transgene for each optoXR mCherry into the AgeI and EcoRI sites of the pLenti SynapsinI hChR2 mCherry WPRE vector.

#### *Lentiviral Production*

High titer lentivirus was produced. Briefly, HEK 293FT cells were plated to 90% confluence in a 4-layer cell factory (Nunc) cultured with DMEM containing 10% FBS. Cells were co-transfected with 690  $\mu$ g of the lentiviral vector described above and two helper plasmids (690  $\mu$ g of p $\Delta$ CMVR8.74 and 460  $\mu$ g of pMD2.G). Media was changed at 15 h post transfection. At 24 h post transfection, media was changed with 200-220 mL of serum free UltraCULTURE (Cambrex) containing 5 mM sodium butyrate. At 40 h post transfection, the culture supernatant, now containing viruses, was spun at 1000 rpm for 5 min to remove cellular debris and then filtered using a 0.45  $\mu$ m low-protein-binding filter flask. The clarified supernatant was then ultra centrifuged for 2 h at 55,000g using an SW 28 rotor (Beckman) to precipitate the virus. After centrifugation, supernatant was discarded and the resultant viral pellet was dissolved in a total of 100  $\mu$ L of cold (4°C) PBS. The resuspended virus was centrifuged for 5 min at 7000 rpm to remove remaining cellular and viral debris. Aliquots were frozen at -80°C until further use.

#### *Animal surgery and behavior*

Female C57BL/6 mice, 10-12 weeks old, were housed and handled according to the Laboratory Vertebrate Animals protocol of Stanford University. Virus solution was delivered to the right nucleus accumbens as follows. Animals were anaesthetized under isoflurane and fur was sheared from the top of the head. While under isoflurane anesthesia, the head of the animal was placed in a stereotactic frame (David Kopf

Instruments). A midline scalp incision was made and a ~1 mm diameter craniotomy was drilled 1.10mm anterior, and 1.45 mm lateral to bregma. A beveled 33 gauge needle (NanoFil, World Precision Instruments) pre-loaded with virus was then lowered into the accumbens (needle tip at 4.70-4.80 mm ventral to bregma) and 1.0  $\mu$ L of virus was  
5 injected at 100 nL/min using an automated syringe pump (NanoFil, World Precision Instruments). Following injection, 3-5 min was allowed for tissue relaxation and fluid diffusion before retraction of the needle. For animals targeted for acute slice or in vivo recording experiments, the craniotomy was filled with dental cement (Lang Dental) and the incision was closed using VetBond (3M). For animals targeted for behavioral  
10 analysis, cannulas (C316G, cut 4.5 mm below the pedestal; PlasticsOne) were placed with the pedestal flush to the skull. Cannulae were secured using Metabond (Parkell) and dental cement (Lang Dental). Following drying of VetBond or cement, animals were removed from the frame and allowed to recover for at least one week before further manipulation. Control animals for behavioral experiments underwent the same  
15 manipulations (surgery, cannula implantation, light stimulation) as experimental animals, and were injected with vehicle (PBS) alone instead of virus. For place preference experiments, animals that did not show a baseline preference for either side chamber (>70% or <10%) or for the central chamber (>40%) were admitted into the study; >90% of all animals met these criteria for an unbiased, balanced place preference design.

#### 20 *Acute slice preparation*

Animals were anaesthetized under isoflurane and decapitated using surgical shears (Fine Science Tools). Coronal, 275  $\mu$ m-thick slices containing accumbens were cut and stored in a cutting solution containing 64mM NaCl, 2.5mM KCl, 1.25mM NaH<sub>2</sub>PO<sub>4</sub>, 25mM NaHCO<sub>3</sub>, 10mM glucose, 120mM sucrose, 0.5mM CaCl<sub>2</sub> and 7mM MgCl<sub>2</sub>  
25 (equilibrated with 95% O<sub>2</sub>/5% CO<sub>2</sub>). Following slicing, slices were incubated in the cutting solution at 32-35°C for 30 min and then at room temperature until experimentation. For *ex vivo* optoXR stimulation, slices were loaded on the stage of an upright microscope (BX51W, Olympus) and perfused with an artificial cerebrospinal fluid containing 124mM NaCl, 3mM KCl, 1.25mM NaH<sub>2</sub>PO<sub>4</sub>, 26mM NaHCO<sub>3</sub>, 10mM  
30 glucose, 2.4mM CaCl<sub>2</sub>, and 1.3mM MgCl<sub>2</sub> (equilibrated with 95% O<sub>2</sub>/5% CO<sub>2</sub>). Light from a 300W Lambda DG-4 (Sutter) was passed through a 473 nm  $\pm$  20 nm bandpass filter (Semrock) and applied to the slices using a 4X objective (0.28 NA) for 10 min followed immediately by fixation for later analysis.

*Signaling validation assays*

HEK293FT cells (Invitrogen) were transfected using Lipofectamine 2000 (Invitrogen) in 24 well plates and changed to serum-free medium 4-6 hrs post-transfection. For  $\text{Ca}^{2+}$  imaging, cells plated on matrigel-coated coverslips were loaded with 5  $\mu\text{g}/\text{ml}$  fura-2 AM in F-127 Pluronic/DMSO (Probes) in Tyrode containing 1  $\mu\text{M}$  ATR, at 37°C and 5% atmospheric  $\text{CO}_2$  for 20-25 min. Following loading, coverslips were imaged at 340nm/380nm on an Olympus BX51 W using Metafluor (Axon Instruments) controlling a 300W Lambda DG-4 (Sutter). For immunoassays, 18-24 hrs after transfection, 1  $\mu\text{M}$  ATR and 50mM LiCl (to prevent  $\text{IP}_1$  degradation) were added and plates transferred to an environmentally-controlled microscope (Leica DMI6000; 37°C, 5% atmospheric  $\text{CO}_2$ ). 5 regions/well were optically stimulated for 1 min each (Sutter 300W Lambda DG-4; Semrock 504/12nm bandpass filter; 10X 0.30 NA objective); 3 wells/condition. Following incubation (cAMP/cGMP: 20 min;  $\text{IP}_1$ : 1 hr), cells were lysed and analyze by HTRF (CisBio) and a Biotek Synergy4 reader.

*Immunohistochemistry and confocal analysis*

Following *in vivo* stimulation, mice were transcardially perfused with ice-cold 4% paraformaldehyde (PFA) in PBS (pH 7.4) 90 min after termination of stimulation. Brains were removed and fixed overnight in 4% PFA and then equilibrated in 30% sucrose in PBS. Coronal, 40  $\mu\text{m}$ -thick sections were cut on a freezing microtome and stored in cryoprotectant at 4°C until processed for immunohistochemistry. Free-floating sections were washed in PBS and then incubated for 30 min in 0.3% Tx100 and 3% normal donkey serum (NDS). For acute slice experiments, immediately following stimulation the 275  $\mu\text{m}$ -thick slices were fixed for 1 hr in ice-cold 4% PFA and incubated with 0.5% Tx100 and 3% NDS. For MAPK assays, immediately following HEK293 cell stimulation, coverslips were fixed for 15 min, incubated with 0.6%  $\text{H}_2\text{O}_2$  and then permeabilized with 0.1% Tx100 in 3% NDS. Primary antibody incubations were conducted overnight in 0.01% Tx100 and 3% NDS for mouse anti-GAD67 1:500, Millipore, Billerica, MA; rabbit anti-cfos 1:500, Calbiochem, San Diego, CA; rabbit anti-phospho-CREB Ser133 1:500, Millipore. Sections were washed and incubated with secondary antibodies (1:1000) conjugated to either FITC or Cy5 (Jackson Laboratories, West Grove, PA) for 3 hrs at room temperature. Following 20 min incubation with DAPI (1:50,000) sections were washed and mounted on microscope slides with PVD-DABCO. The remaining overnight primary antibody incubations (rabbit anti-phosphoErk1/2; anti-

phospho-MAPK p38 1:500, Promega, Madison, WI; mouse monoclonal anti-dopamine D1 receptor 1:50, Chemicon; rabbit polyclonal anti-dopamine D2 receptor 1:50, Millipore; goat polyclonal anti-choline acetyltransferase 1:200, Millipore) were followed by incubation with biotinylated secondary antibody (1:500, Jackson Laboratories), avidin-  
 5 biotin-horseradish peroxidase treatment (ABC kit, Vector Labs, Burlingame, CA), and TSA detection (Perkin Elmer, Shelton, CT) according to manufacturer's instructions.

Confocal fluorescence images were acquired on a Leica TCS SP5 scanning laser microscope using a 20X/0.70NA or a 40X/1.25NA oil immersion objective. Four serial stack images per condition were acquired within a 500  $\mu$ m region beneath the cannula  
 10 tract. DAPI staining was used to delineate nuclei for determination of the mean pixel intensity of cfos or pCREB immunoreactivity using Volocity (Improvision) software. Positive or pCREB-active cells were identified by intensity threshold, and image acquisition and analysis were performed blind to the experimental conditions.

#### 15 **Table S1**

Raw numerical pCREB intensities (au) for data represented in FIG. 3B. Mean and SEM in bold for each subgroup; p-values for two-tailed t-test of subgroup versus control in italics.

	opto- $\alpha_1$ AR		opto- $\beta_2$ AR	
mCherry	-	+	-	+
Mean	65.326	97.95309	63.6385	82.83284
SEM	3.758281	7.199024	3.847409	6.907057
<b>p-value vs. mCherry-</b>		<i>0.000272</i>		<i>0.019559</i>

#### 20 **Table S2**

Raw numerical baseline firing rates (Hz) for data presented in FIG. 4A. Mean and SEM in bold for each subgroup; p-values for t-test of subgroup versus control in italics.

	XFP	$\alpha_1$ AR	$\beta_2$ AR
Mean	2.596154	2.439357	2.687798
SEM	0.436406	0.603845	0.346556
<b>p-value vs XFP</b>		<i>0.834496</i>	<i>0.869791</i>

**Table S3**

Raw numerical changes in firing rate (Hz) for data presented in FIG. 4C calculated within the baseline itself ('Base') and between the baseline and the light stimulation periods ('Light').

	opto- $\beta_2$ AR		Opto- $\alpha_1$ AR	
	Base	Light	Base	Light
Mean	0.061788	-0.68113	-0.01287	3.816198
SEM	0.134665	0.162402	0.336387	0.812251
<b>p-value vs Base</b>		<i>0.000861</i>		<i>0.000239</i>

5

Accordingly, embodiments of the present invention relate to optogenetic control of intracellular signaling and are useful for temporally precision while operating *in vivo* within behaving mammals, while displaying extremely low dark activity, and recruiting the complex fabric of multiple signaling molecules downstream of native receptors, thereby unifying in a single technology many of the individual positive aspects of other approaches. Similar embodiments directly probe the causal significance of seven-transmembrane-dependent signaling pathways triggered by other modulators, including myriad neurotransmitters and endocrine hormones. Other embodiments use an optoXR approach in ways that extend beyond excitable cells to capitalize upon the versatile integration of fiber-optic depth targeting with optogenetically targeted photosensitivity. One such embodiment relates to probing causal significance of temporally precise biochemical signaling in diverse non-excitable tissues.

Embodiments of the present invention relate to considerations of the phenomenon of ligand-biased signaling, wherein varied ligands can stabilize ensemble receptor conformational states and thereby bias the intracellular action of the receptor in coupling to alternative transduction cascades. The optoXRs are used to induce these alternative cascades to similar levels as with pharmacological manipulation (for example, opto- $\beta_2$ AR can induce similar changes in MAPK activation compared with native ligand acting on the wild-type  $\beta_2$ AR); however, individual optoXRs may not always be found to permit control of all of the conformational states that contribute to ligand biased signaling. Retinal-based tools can be particularly useful due to the presence of the endogenous chromophore in mammalian tissues, and the extremely low activity in the dark.

Optogenetics can take the form of diverse effectors linked to fast, single-component retinal-binding modules, capitalizing on the temporal precision of optics.

Embodiments of the present invention use optoXR methods to complement microbial opsin strategies, providing another dimension of fast, targetable cellular control  
5 operative in behaving mammals.

Consistent with another embodiment of the present invention, wavelength-shifted versions of the optoXRs, based on known opsin genes with different action spectra, are used. Such optoXRs can be particularly useful for providing separable channels of biochemical and electrical control.

10 Variants of the specific protein sequences discussed herein are consistent with embodiments of the present invention. Some variants are greater than about 75% homologous to these protein sequences, while others are greater than about 80%, 85% or 90%. In some embodiments the homology will be as high as about 93 to about 95 or about 98%. The compositions of the present invention include the protein and nucleic  
15 acid sequences provided herein including variants which are more than about 50% homologous to the provided sequence up to and including 100% homologous.

The various embodiments discussed herein could be integrated with fast circuit readout technologies for increasingly sophisticated interrogation and reverse engineering of neural circuitry, both in normal operation and in disease states.

20 The various embodiments described above are provided by way of illustration only and should not be construed to limit the invention. Based on the above discussion and illustrations, those skilled in the art will readily recognize that various modifications and changes may be made to the present invention without strictly following the exemplary embodiments and applications illustrated and described herein. For instance,  
25 such changes may include variations of the secondary messenger produced. Such modifications and changes do not depart from the true spirit and scope of the present invention, which is set forth in the following claims.

**THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:**

1. A method for generating secondary messengers in a cell, the method comprising:  
expressing in the cell a chimeric light-responsive fusion protein comprising a light-responsive rhodopsin-based membrane protein and a heterologous alpha-1 adrenergic receptor, wherein said expression provides for production of a secondary messenger in response to light, and wherein the chimeric light-responsive fusion protein comprises an amino acid sequence having at least 85% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO: 4,  
wherein the cell expresses a secondary messenger-targeted cation channel that is responsive to the secondary messenger; and  
visualizing resultant activity using a cation-sensitive dye.
2. The method according to claim 1, wherein the chimeric light-responsive fusion protein is a seven transmembrane protein.
3. The method according to claim 1 or 2, wherein the secondary messenger is inositol trisphosphate/inositol 1,4,5-trisphosphate/triphosphoinositol (IP<sub>3</sub>).
4. The method according to any one of claims 1 to 3, wherein the step of expressing is accomplished *in vivo*.
5. The method according to any one of claims 1 to 3, wherein the step of expressing is accomplished *in vitro*.
6. The method according to any one of claims 1 to 5, further comprising optically stimulating the expressed chimeric light-responsive fusion protein.
7. The method according to claim 6, wherein the step of optically stimulating the expressed chimeric light-responsive fusion protein comprises applying light through an optical fiber.
8. The method according to claim 6, wherein the step of optically stimulating the expressed chimeric light-responsive fusion protein comprises applying a pulsatile optical stimulus.



9. The method according to any one of claims 1 to 8, wherein a nucleotide sequence encoding the chimeric light-responsive fusion protein comprises a sequence having at least 90% nucleotide sequence identity to SEQ ID NO: 3.

10. The method according to any one of claims 1 to 9, wherein the nucleotide sequence is operably linked to a cell type-specific promoter.

11. The method according to claim 10, wherein the cell type-specific promoter is a neuron-specific promoter.

12. The method according to claim 10, wherein the cell type-specific promoter is a synapsin-1 promoter.

13. The method according to any one of claims 1 to 8 or 10 to 12, wherein the chimeric light-responsive fusion protein comprises an amino acid sequence having at least 90% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO: 4.

14. The method according to any one of claims 1 to 8 or 10 to 13, wherein the chimeric light-responsive fusion protein comprises an amino acid sequence having at least 95% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO: 4.

15. A method for assessing the efficacy of a treatment regimen relating to intracellular messengers, the method comprising:

expressing a chimeric light-responsive fusion protein comprising a light-responsive rhodopsin-based membrane protein and a heterologous alpha-1 adrenergic receptor in a mammalian cell, wherein said expression provides for production of a secondary messenger in response to light, and wherein the chimeric light-responsive fusion protein comprises an amino acid sequence having at least 85% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO: 4;

wherein the cell expresses a secondary messenger-targeted cation channel that is responsive to the secondary messenger;

exposing the chimeric light-responsive fusion protein to light; and

assessing the effects of the treatment by visualizing resultant activity using a cation-sensitive dye.

16. A cell suitable for use in the method according to any one of claims 1 to 15, the cell expressing:

a) a chimeric light responsive rhodopsin-based membrane protein with one or more heterologous alpha-1 receptor subunits, wherein the chimeric protein produces a second messenger, and wherein the chimeric protein comprises an amino acid sequence having at least 85% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO: 4; and

b) a secondary messenger-targeted cation channel that is responsive to the second messenger.

17. A cell suitable for use in the method according to any one of claims 1 to 15, the cell expressing a polypeptide comprising an amino acid sequence having at least 90% amino acid sequence homology to the amino acid sequence set forth in SEQ ID NO: 4.

18. The cell according to claim 17, wherein the polypeptide consists of an amino acid sequence set forth in SEQ ID NO: 4.

19. A non-human transgenic mammal comprising a cell expressing a chimeric light-responsive fusion protein comprising a light-responsive rhodopsin-based membrane protein and a heterologous alpha-1 adrenergic receptor, wherein the chimeric light-responsive fusion protein comprises an amino acid sequence having at least 85% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO: 4, wherein expression of the fusion protein in the cell provides for production of a secondary messenger in the cell in response to light.

20. The non-human transgenic mammal according to claim 19, wherein the non-human transgenic mammal is a mouse.

21. A chimeric light-responsive fusion protein comprising a light-responsive rhodopsin-based membrane protein and a heterologous alpha-1 adrenergic receptor, wherein the chimeric light-responsive fusion protein comprises an amino acid sequence

having at least 85% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO: 4.

22. The chimeric light-responsive fusion protein according to claim 21, wherein the chimeric light-responsive fusion protein comprises an amino acid sequence having at least 90% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO: 4.

23. The chimeric light-responsive fusion protein according to claim 21 or 22, wherein the chimeric light-responsive fusion protein comprises an amino acid sequence having at least 95% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO: 4.

24. The chimeric light-responsive fusion protein according to any one of claims 21 to 23, wherein expression of the chimeric light-responsive fusion protein in a mammalian cell provides for production of a secondary messenger in the cell in response to light.

25. The chimeric light-responsive fusion protein according to claim 24, wherein the secondary messenger is inositol trisphosphate/inositol 1,4,5-trisphosphate/triphosphoinositol (IP<sub>3</sub>).

26. The chimeric light-responsive fusion protein according to any one of claims 21 to 25, wherein the chimeric light-responsive fusion protein is encoded by a nucleotide sequence that is operably linked to a cell type-specific promoter.

27. The chimeric light-responsive fusion protein according to claim 26, wherein the cell type-specific promoter is a neuron-specific promoter.

28. The chimeric light-responsive fusion protein according to claim 27, wherein the promoter is a synapsin-1 promoter.

29. A nucleic acid molecule encoding a chimeric light-responsive fusion protein, wherein the chimeric light-responsive fusion protein comprises a light-responsive rhodopsin-based membrane protein and a heterologous alpha-1 adrenergic receptor, and

wherein the nucleic acid molecule has at least 90% nucleotide sequence identity to SEQ ID NO: 3.

30. A recombinant expression vector comprising the nucleic acid molecule according to claim 29.

31. A cell genetically modified with the nucleic acid molecule according to claim 29 or the vector according to claim 30.

32. The cell according to claim 31, wherein the cell is a mammalian cell.

33. The cell according to claim 31 or 32, wherein the cell is a neuron.


34. The method according to any one of claims 1 to 15 or the cell according to any one of claims 16 to 18 or 30 or 31 or the non-human transgenic mammal according to claim 19 or 20 or the chimeric light-responsive protein according to 21 to 28 or the nucleic acid molecule according to claim 29 or the recombinant expression vector according to claim 30 substantially as hereinbefore described with reference to the accompanying drawings and/or examples.

DATED this NINETEENTH day of MAY, 2014


**The Board of Trustees of the Leland  
Stanford Junior University**

*By patent attorneys for the applicant:*

*FB Rice*




**FIG. 1**



**FIG. 2**

3/5

**FIG. 3**

SUBSTITUTE SHEET (RULE 26)





FIG. 4





**FIG. 5**

## SEQUENCE LISTING

<110> Airan, Raag  
Deisseroth, Karl

<120> CELL LINE, SYSTEM AND METHOD FOR OPTICAL CONTROL OF SECONDARY  
MESSENGERS

<130> STFD.195PCT

<140> PCTUS0945611

<141> 2009-05-29

<150> US 61/057,108

<151> 2008-05-29

<160> 4

<170> PatentIn version 3.5

<210> 1

<211> 1302

<212> DNA

<213> Artificial Sequence

<220>

<223> rhodopsin/GPCR chimerism

<400> 1

atgaacggaa cagagggccc aaacttttac gttcccttct ccaataagac tggggtcgtg	60
agaagcccat ttgaggcgcc tcaatactac cttgctgagc cgtggcagtt ttctatgctc	120
gctgcttaca tgttcttget gatcatgctg gggttcccta tcaatttcct gacgctgtac	180
gttatagcaa agttcgaacg cctccaaacc gtgttgaact acatactcct taacctcgcg	240
gttgccgacc tcttcatggt tttcgggggt ttcaccacca ccctctacac ctcccttcac	300
ggctacttcg tgttcggccc taccggatgc aatctggaag gctttttcgc aacgctgggg	360
ggggagattg ccctttggag cctggtggtc ttggccatag agaggtacgt ggtggtcaca	420
tccccattca agtaccagag tttgcttaca aagaacaagg ctatcatggg ggtcgccttc	480
acatgggtga tggcgctggc ttgcgctgcc ccaccgctgg taggctggtc ccggtatatt	540
ccggagggaa tgcagtgcag ttgtgggatc gactactaca ccccacacga agagactaac	600
aacgagtctt ttgtgattta tatgttcgtg gtccacttca tcatccccct gatagtgatc	660
tttttctgtt acggcagggg gttccaggtc gccaaaaggc agctccagaa gatcgacaaa	720
agcgaaggcc gctttcacag cccaatctt ggacagggtg aacaggacgg caggtcaggg	780
cacgggctgc gacgcagttc taagttctgc ctgaaggaac ataaggcctt gagaatggtg	840

atcatcatgg taatcgctt cctgatatgc tggcttccat acgctggcgt ggctttttat	900
atattcacgc accaggggtc agattttggg cctatcttta tgaccatacc tgctttcttc	960
gctaagacga gtgcggtgta taaccacagt atatacatca tgatgaacaa acaattcaga	1020
attgccttcc aggaattgct ctgtctcaga cgcagctctt ccaaagcgta cggaaatggc	1080
tattcatcta acagcaacgg aaagactgat tatatgggcg aagccagtgg ctgccagctg	1140
ggccaggaaa aagagagcga gcggctttgt gaagatccc caggcactga gagcttcgtg	1200
aattgtcagg gaacagttcc gagtctctct cttgattcac agggacgcaa ttgctctacc	1260
aacgacagcc ccttgagac ttcccaggtc gctccggcct aa	1302

<210>	2
<211>	434
<212>	PRT
<213>	Artificial Sequence
<220>	
<223>	rhodopsin/GPCR chimerism
<400>	2

Val Val Leu Ala Ile Glu Arg Tyr Val Val Val Thr Ser Pro Phe Lys  
130 135 140

Tyr Gln Ser Leu Leu Thr Lys Asn Lys Ala Ile Met Gly Val Ala Phe  
145 150 155 160

Thr Trp Val Met Ala Leu Ala Cys Ala Ala Pro Pro Leu Val Gly Trp  
165 170 175

Ser Arg Tyr Ile Pro Glu Gly Met Gln Cys Ser Cys Gly Ile Asp Tyr  
180 185 190

Tyr Thr Pro His Glu Glu Thr Asn Asn Glu Ser Phe Val Ile Tyr Met  
195 200 205

Phe Val Val His Phe Ile Ile Pro Leu Ile Val Ile Phe Phe Cys Tyr  
210 215 220

Gly Arg Val Phe Gln Val Ala Lys Arg Gln Leu Gln Lys Ile Asp Lys  
225 230 235 240

Ser Glu Gly Arg Phe His Ser Pro Asn Leu Gly Gln Val Glu Gln Asp  
245 250 255

Gly Arg Ser Gly His Gly Leu Arg Arg Ser Ser Lys Phe Cys Leu Lys  
260 265 270

Glu His Lys Ala Leu Arg Met Val Ile Ile Met Val Ile Ala Phe Leu  
275 280 285

Ile Cys Trp Leu Pro Tyr Ala Gly Val Ala Phe Tyr Ile Phe Thr His  
290 295 300

Gln Gly Ser Asp Phe Gly Pro Ile Phe Met Thr Ile Pro Ala Phe Phe  
305 310 315 320

Ala Lys Thr Ser Ala Val Tyr Asn Pro Val Ile Tyr Ile Met Met Asn  
325 330 335

Lys Gln Phe Arg Ile Ala Phe Gln Glu Leu Leu Cys Leu Arg Arg Ser  
340 345 350

Ser Ser Lys Ala Tyr Gly Asn Gly Tyr Ser Ser Asn Ser Asn Gly Lys  
355 360 365

Thr Asp Tyr Met Gly Glu Ala Ser Gly Cys Gln Leu Gly Gln Glu Lys  
370 375 380

Glu Ser Glu Arg Leu Cys Glu Asp Pro Pro Gly Thr Glu Ser Phe Val  
385 390 395 400

Asn Cys Gln Gly Thr Val Pro Ser Leu Ser Leu Asp Ser Gln Gly Arg  
405 410 415

Asn Cys Ser Thr Asn Asp Ser Pro Leu Thr Glu Thr Ser Gln Val Ala  
420 425 430

Pro Ala

<210> 3  
<211> 1485  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> rhodopsin/GPCR chimerism

<400> 3  
atgaatggga ccgagggtec aaatttttac gtacccttta gtaacaagac tggcgtggtg 60  
cgcagtccat tcgaagcccc acagtactac ctcgcagagc cgtggcaatt ctcaatgctg 120  
gccgcttata tgttccttct gattatgctg gggtttccca tcaattttct taccctgtat 180  
gtggtagcat gccacagaca ttgcactcc gtattgaatt atattcttct gaacctcgcg 240  
gtggcagatc ttttcatggg gttcggcggg ttacgacta ctctgtatac gtccttgcac 300  
ggttattttg tgttcgggcc cacaggctgc aacttgaag gcttcttcgc cactcttggc 360  
ggtgagatcg ctctttggag cctggtcgtc ctggccatcg agcggtatgt ggtggtgtct 420  
taccctctca gatatccac catagtgacc cagcggaggg ccattatggg tgtagccttt 480  
acctgggtca tggctttggc ctgtgctgct cccccctgg tgggttggtc ccgctatatt 540  
ccagaaggta tgcagtgttc ttgcggaatc gactactata ccccgcacga agagacaaac 600  
aacgagtcct tcgtcatata tatgtttgta gtccacttta tcatccccctt gattgttatt 660  
tttttttgct atggacgcgt ctacgtcgtg gccaaaaggg agtccagggg cttgaaatct 720

ggactgaaga cagataagag cgattccgag caggtgaccc ttcgcattca taggaagaac 780  
 gccccagcag gcggaagcgg gatggcatcc gccaaagacta aaaccactt ttccgtgcgg 840  
 cttctcaagt tctcccgca gaaaaaggcg gcgcgcgatgg tcatcatcat ggttatcgcc 900  
 tttctcattt gctggtgcc ttacgtgga gtcgcgtttt acatcttcac acatcaaggt 960  
 tctgactteg gcccaatctt tatgaccatc cctgccttct tcgccaagac ctctgccgtg 1020  
 tataaccccg ttatctatat tatgatgaac aagcagttcc ggaaggcatt tcagaatgtg 1080  
 ctgagaatcc aatgcctctg tcggaagcag tctagtaagc atgccctggg gtatactctg 1140  
 caccaccca gtcaggctgt agaggccaa cacaaggata tggcgcgat accagtcggt 1200  
 tccagggaga cattttatcg gattagtaag accgacggag tctgcgagtg gaagtttttc 1260  
 tcttccatgc ccaggggatc tgcaaggatc acagtttcta aggatcagtc cagctgtacc 1320  
 acagcccggc tgcgctcaa atcctttctt caggtctgct gctgtgttgg ccctcaacc 1380  
 ccctccctcg ataagaacca tcaggttccc accatcaagg tgcacactat atccttgagc 1440  
 gaaaacggcg aggaagttga aacttcacag gttgcccccg cctaa 1485

<210> 4  
 <211> 495  
 <212> PRT  
 <213> Artificial Sequence  
  
 <220>  
 <223> rhodopsin/GPCR chimerism  
  
 <400> 4

Met Asn Gly Thr Glu Gly Pro Asn Phe Tyr Val Pro Phe Ser Asn Lys  
 1 5 10 15

Thr Gly Val Val Arg Ser Pro Phe Glu Ala Pro Gln Tyr Tyr Leu Ala  
 20 25 30

Glu Pro Trp Gln Phe Ser Met Leu Ala Ala Tyr Met Phe Leu Leu Ile  
 35 40 45

Met Leu Gly Phe Pro Ile Asn Phe Leu Thr Leu Tyr Val Val Ala Cys  
 50 55 60

His Arg His Leu His Ser Val Leu Asn Tyr Ile Leu Leu Asn Leu Ala  
 65 70 75 80

Val	Ala	Asp	Leu	Phe	Met	Val	Phe	Gly	Gly	Phe	Thr	Thr	Thr	Leu	Tyr	85	90	95	
Thr	Ser	Leu	His	Gly	Tyr	Phe	Val	Phe	Gly	Pro	Thr	Gly	Cys	Asn	Leu	100	105	110	
Glu	Gly	Phe	Phe	Ala	Thr	Leu	Gly	Gly	Glu	Ile	Ala	Leu	Trp	Ser	Leu	115	120	125	
Val	Val	Leu	Ala	Ile	Glu	Arg	Tyr	Val	Val	Val	Ser	Tyr	Pro	Leu	Arg	130	135	140	
Tyr	Pro	Thr	Ile	Val	Thr	Gln	Arg	Arg	Ala	Ile	Met	Gly	Val	Ala	Phe	145	150	155	160
Thr	Trp	Val	Met	Ala	Leu	Ala	Cys	Ala	Ala	Pro	Pro	Leu	Val	Gly	Trp	165	170	175	
Ser	Arg	Tyr	Ile	Pro	Glu	Gly	Met	Gln	Cys	Ser	Cys	Gly	Ile	Asp	Tyr	180	185	190	
Tyr	Thr	Pro	His	Glu	Glu	Thr	Asn	Asn	Glu	Ser	Phe	Val	Ile	Tyr	Met	195	200	205	
Phe	Val	Val	His	Phe	Ile	Ile	Pro	Leu	Ile	Val	Ile	Phe	Phe	Cys	Tyr	210	215	220	
Gly	Arg	Val	Tyr	Val	Val	Ala	Lys	Arg	Glu	Ser	Arg	Gly	Leu	Lys	Ser	225	230	235	240
Gly	Leu	Lys	Thr	Asp	Lys	Ser	Asp	Ser	Glu	Gln	Val	Thr	Leu	Arg	Ile	245	250	255	
His	Arg	Lys	Asn	Ala	Pro	Ala	Gly	Gly	Ser	Gly	Met	Ala	Ser	Ala	Lys	260	265	270	
Thr	Lys	Thr	His	Phe	Ser	Val	Arg	Leu	Leu	Lys	Phe	Ser	Arg	Glu	Lys	275	280	285	
Lys	Ala	Ala	Arg	Met	Val	Ile	Ile	Met	Val	Ile	Ala	Phe	Leu	Ile	Cys	290	295	300	

Trp	Leu	Pro	Tyr	Ala	Gly	Val	Ala	Phe	Tyr	Ile	Phe	Thr	His	Gln	Gly	305	310	315	320
Ser	Asp	Phe	Gly	Pro	Ile	Phe	Met	Thr	Ile	Pro	Ala	Phe	Phe	Ala	Lys	325	330	335	
Thr	Ser	Ala	Val	Tyr	Asn	Pro	Val	Ile	Tyr	Ile	Met	Met	Asn	Lys	Gln	340	345	350	
Phe	Arg	Lys	Ala	Phe	Gln	Asn	Val	Leu	Arg	Ile	Gln	Cys	Leu	Cys	Arg	355	360	365	
Lys	Gln	Ser	Ser	Lys	His	Ala	Leu	Gly	Tyr	Thr	Leu	His	Pro	Pro	Ser	370	375	380	
Gln	Ala	Val	Glu	Gly	Gln	His	Lys	Asp	Met	Val	Arg	Ile	Pro	Val	Gly	385	390	395	400
Ser	Arg	Glu	Thr	Phe	Tyr	Arg	Ile	Ser	Lys	Thr	Asp	Gly	Val	Cys	Glu	405	410	415	
Trp	Lys	Phe	Phe	Ser	Ser	Met	Pro	Arg	Gly	Ser	Ala	Arg	Ile	Thr	Val	420	425	430	
Ser	Lys	Asp	Gln	Ser	Ser	Cys	Thr	Thr	Ala	Arg	Val	Arg	Ser	Lys	Ser	435	440	445	
Phe	Leu	Gln	Val	Cys	Cys	Cys	Val	Gly	Pro	Ser	Thr	Pro	Ser	Leu	Asp	450	455	460	
Lys	Asn	His	Gln	Val	Pro	Thr	Ile	Lys	Val	His	Thr	Ile	Ser	Leu	Ser	465	470	475	480
Glu	Asn	Gly	Glu	Glu	Val	Thr	Glu	Thr	Ser	Gln	Val	Ala	Pro	Ala		485	490	495	